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million. Within the adjunct group, growth factors (at
4.2%) accounted for the largest proportion of the cost in-
crease, while antiemetics (the largest dollar amount) de-
creased between 1995 and 1998. CONCLUSION: Che-
motherapy accounted for the majority of the total increase
in pharmaceutical cost in-patients with cancer. Drugs
used in the treatment of routine conditions (i.e., not can-
cer-related) were the second largest cost drivers. Support-
ive therapy was the third largest cost driver. Of the groups
studied, chemotherapy adjuncts had the smallest impact
on total drug cost increases.
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OBJECTIVE: To determine treatment patterns and cost
associated with the management of lung cancer in France
from the perspective of French hospitals by means of a
retrospective chart review. METHODS: Estimates were
based on a retrospective review of medical care consump-
tion in patients diagnosed with either small cell lung can-
cer (SCLC) or non small cell lung cancer (NSCLC) be-
tween 06/98 and 06/99 and followed until 09/99. Quotas
were defined by type and stage of lung cancer according
to available epidemiological data. Patients were identified
at a representative sample of 11 hospital centres in
France. Costs were estimated from date of diagnosis until
death or 16 months follow-up. Costs were adjusted for
censoring by means of a method described by Lin et al.
(Biometrics, 1997). RESULTS: 439 patient charts were
reviewed, including 92 SCLC and 357 NSCLC. Mean age
at diagnosis was 62, sex ratio was 82% male, 18% fe-
male. Survival at 12 months was 36% for SCLC and
ranged between 79% and 32% for NSCLC depending on
stage at diagnosis. All patients with limited-stage SCLC
received chemotherapy and 84% benefited from radio-
therapy. Of patients with disseminated SCLC, 91% re-
ceived chemotherapy and 49% palliative radiotherapy.
Patients with stage I–III NSCLC were treated with sur-
gery (43%), chemotherapy (71%) and/or radiotherapy
(73%). Stage IV NSCLC patients had surgery (15%) and/
or chemotherapy (91%) and/or radiotherapy (65%). Pre-
liminary analyses indicate that the management of ad-
verse events accounted for more than 25% of the total
cost. CONCLUSION: Considering the high cost manage-
ment of adverse events and radiotherapy, new chemo-
therapy treatments increasing overall survival with ac-
ceptable toxicity profile and decreasing radiotherapy acts,
would have a significant economic value. Updated results
will be presented.
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OBJECTIVES: To study the cost of cancer pain manage-
ment in the Maccabi database. This database delivers in-
formation on diagnosis, treatment and costs. Costs were
compared for patients that were on MOR and switched
to FEN and costs were assessed relative to total treatment
cost. METHODS: A selection was made of all cancer pa-
tients (N  1082) treated with strong opioids during
1997–1998. Fifty-two percent were women and average
age 62 years. Fifteen percent of the patients had skin can-
cer and 10% was reported with lung cancer. Patients
were divided in four different groups based upon the se-
quence of strong opioid use: FF is the group that was on
FEN, MF was the group that started on MOR but
switched to FEN, FM vice versa and MM were on MOR
throughout. RESULTS: In the MF group significantly
fewer infections and abdominal pain were reported by
patients after switching to FEN. Also a reduction in
drugs used was observed after switching to FEN: laxa-
tives, H2-blockers, anti-emetics, anti-diarrhea, antibiot-
ics, NSAIDs and other pain treatments. The total mean
daily drug acquisition cost was 162 New Israelian Shekel
(NIS) for the MOR period and 115 NIS while on FEN, a
reduction resulting from reduced need for concomittant
medication. The cost for pain management accounted for
3.1% (MM) to 6.7% (MF) of the total expenses, indicat-
ing the relatively low impact the choice of pain strategy
has on total cost. CONCLUSION: This database analysis
indicates that FEN treatment generates fewer costs com-
pared to MOR treatment in patients switching from
MOR to FEN. Without an adequate control group it is
difficult to determine whether this reflects resource utili-
zation related to the selected pain treatment or changed
medical practice in the course of cancer treatment. Over-
all the cost of pain management is low relative to the to-
tal cost for these patients.
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QoL is an important factor in the evaluation of new can-
cer therapies. Conventional analyses of responses in ther-
apeutic trials fail to account for treatment effects on pa-
tient’s perception of their health status and their general
well being. OBJECTIVE: To develop a methodology for
